What is the primary difference between hydroxocobalamin and cyanocobalamin in terms of pharmaceutical use?

Hydroxocobalamin is primarily used as an immediate-acting antidote for cyanide poisoning by binding free cyanide ions. It is also a therapeutic form of vitamin B12. Cyanocobalamin is the most common synthetic form of vitamin B12 used for treating deficiencies, but it does not possess the rapid cyanide-binding properties of hydroxocobalamin.

Are there specific storage conditions required for hydroxocobalamin API?

Yes, hydroxocobalamin API is typically sensitive to light and should be stored in well-closed, light-resistant containers at controlled room temperature or as specified by the manufacturer's stability data to maintain its potency and prevent degradation.

What is the typical lead time for sourcing hydroxocobalamin API from major suppliers?

Lead times can vary significantly based on the supplier's production schedules, current inventory, order volume, and the client's regulatory status. For large quantities or new clients, lead times can range from 8 to 24 weeks, especially if batch production needs to be scheduled.

Does the manufacturing process for hydroxocobalamin involve any specific hazardous materials?

The synthesis of complex organic molecules like hydroxocobalamin may involve the use of various reagents and solvents. Manufacturers are required to have robust safety protocols in place to manage any hazardous materials used during the chemical synthesis process and to ensure no harmful residues remain in the final API.

What are the implications of impurities in hydroxocobalamin API for patient safety?

Impurities, if not controlled within pharmacopoeial limits, can pose significant risks to patient safety. They can reduce the API's efficacy, cause adverse drug reactions, or exhibit their own toxic effects. Rigorous quality control and analytical testing are therefore essential to identify and quantify any impurities.

hydroxocobalamin: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Btg Intl	CYANOKIT	hydroxocobalamin	INJECTABLE;INJECTION	022041	NDA	BTG INTERNATIONAL INC.	50633-310-11	1 VIAL, GLASS in 1 CARTON (50633-310-11) / 250 mL in 1 VIAL, GLASS	2021-12-15
Actavis	HYDROXOCOBALAMIN	hydroxocobalamin	INJECTABLE;INJECTION	085998	ANDA	Actavis Pharma, Inc.	0591-2888-30	1 VIAL, MULTI-DOSE in 1 CARTON (0591-2888-30) / 30 mL in 1 VIAL, MULTI-DOSE	2010-11-12
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key global suppliers of hydroxocobalamin, a critical active pharmaceutical ingredient (API) used in treating cyanide poisoning and vitamin B12 deficiency. The report details manufacturing capabilities, regulatory approvals, and market presence of leading companies.

Who Are the Primary Manufacturers of Hydroxocobalamin API?

The production of high-quality hydroxocobalamin API is concentrated among a limited number of specialized pharmaceutical chemical manufacturers. These entities possess the advanced synthesis capabilities and stringent quality control required for pharmaceutical-grade production.

The principal suppliers include:

Fresenius Kabi AG: A global healthcare company that manufactures and markets injectable drugs and technologies for infusion, transfusion, and clinical nutrition. They are a significant producer of hydroxocobalamin, particularly for its use in cyanide antidote kits. Their product, Cyanokit, is widely distributed.
Merck KGaA (MilliporeSigma): While more known for its life science research products, Merck KGaA, through its subsidiary MilliporeSigma in the U.S. and Canada, supplies a range of pharmaceutical ingredients. They offer hydroxocobalamin as part of their portfolio for pharmaceutical manufacturing.
Shin Poong Pharmaceutical Co., Ltd.: A South Korean pharmaceutical company with a focus on APIs and finished dosage forms. They are a known producer of hydroxocobalamin API.
Nanjing Legend Biotechnology Co., Ltd.: A China-based biopharmaceutical company involved in the research, development, and manufacturing of APIs and intermediates, including hydroxocobalamin.
Qilu Pharmaceutical Co., Ltd.: Another significant Chinese pharmaceutical manufacturer that produces a variety of APIs. Hydroxocobalamin is within their production scope.

Manufacturing Capacity and Specialization

Manufacturers differentiate themselves through production scale, adherence to Good Manufacturing Practices (GMP), and specific product purity profiles.

Company	Primary Focus/Product Line	Key Markets Served	Notes
Fresenius Kabi AG	Cyanide Antidote Kits (Cyanokit), Injectable APIs	Global (North America, Europe, Asia)	FDA and EMA approved product available
Merck KGaA (MilliporeSigma)	Broad API portfolio, Reagents	Global (Research & Pharmaceutical)	Supply chain reliability is a key aspect
Shin Poong Pharma	Vitamins, APIs (including Hydroxocobalamin)	Asia, Emerging Markets	Strong presence in Korean and Asian markets
Nanjing Legend Bio	APIs, Intermediates	China, Global Exports	Focus on cost-effective synthesis
Qilu Pharmaceutical	Diverse API portfolio	China, Global Exports	Large-scale production capabilities

Fresenius Kabi is a leading integrated supplier, offering both the API and the finished drug product, often positioning itself as a primary source for emergency medical supplies. Other manufacturers may focus on supplying the API to generic drug makers or other pharmaceutical companies for formulation.

What Regulatory Approvals Are Required for Hydroxocobalamin Production?

Production of pharmaceutical-grade hydroxocobalamin requires adherence to rigorous regulatory standards set by health authorities worldwide. The primary approvals concern manufacturing site registration, API Master File (APIMF) or Drug Master File (DMF) submissions, and compliance with current Good Manufacturing Practices (cGMP).

Key Regulatory Bodies and Requirements

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA’s cGMP regulations (21 CFR Parts 210 and 211). A U.S. DMF detailing the manufacturing process, controls, and specifications must be filed with the FDA.
European Medicines Agency (EMA): For the European Union, manufacturers must comply with EU GMP guidelines. A European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of Suitability (CEP) is often required, which attests that the API complies with the European Pharmacopoeia (Ph. Eur.) monograph. An APIMF can also be filed.
Other National Authorities: Agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and other countries have similar stringent requirements, often referencing international guidelines like ICH (International Council for Harmonisation).

Pharmacopoeia Standards

Hydroxocobalamin API must meet the specifications outlined in major pharmacopoeias, including:

United States Pharmacopeia (USP): Provides the official standards for identity, strength, quality, and purity.
European Pharmacopoeia (Ph. Eur.): Sets similar standards for the European market.
Japanese Pharmacopoeia (JP): The standard for Japan.

Compliance with these monographs ensures the API is safe and effective for its intended therapeutic use. Manufacturers must demonstrate robust analytical testing and validation procedures.

What is the Competitive Landscape and Market Dynamics?

The hydroxocobalamin market is characterized by a balance between established global players, particularly those with integrated product offerings, and emerging suppliers focusing on API manufacturing. Market demand is driven by its critical role in emergency medicine and its therapeutic benefits for vitamin B12 deficiencies.

Market Drivers

Cyanide Poisoning Treatment: The increasing incidence of industrial accidents and intentional poisonings, coupled with advancements in emergency medical response protocols, sustains demand for hydroxocobalamin as a first-line antidote.
Vitamin B12 Deficiency Treatment: Growing awareness of vitamin B12 deficiency and its associated health risks (neurological disorders, anemia) drives demand for hydroxocobalamin in injectable and oral formulations.
Generic Drug Market: The expiry of patents on branded hydroxocobalamin products opens opportunities for generic manufacturers, increasing the demand for API from specialized suppliers.

Challenges and Opportunities

Supply Chain Resilience: Given the critical nature of hydroxocobalamin, ensuring a robust and secure supply chain is paramount. Geopolitical factors, raw material sourcing, and manufacturing disruptions can impact availability.
Regulatory Hurdles: Navigating the complex and evolving regulatory landscapes across different countries presents a significant barrier to entry for new manufacturers.
Cost Pressures: While quality is paramount, there is continuous pressure to reduce manufacturing costs for APIs, particularly for generic applications.
Emerging Markets: Expanding healthcare infrastructure and increasing access to medicines in developing countries represent significant growth opportunities for hydroxocobalamin suppliers.

Key Competitors and Their Strategies

Fresenius Kabi's strategy centers on its integrated approach, offering a complete antidote solution. This includes not only the API but also the specialized presentation and regulatory approval for emergency use, creating a high barrier for competitors in this niche.

Companies like Shin Poong, Nanjing Legend Biotechnology, and Qilu Pharmaceutical focus on cost-competitive API production, aiming to capture market share by supplying generic drug formulators globally. Their success depends on meeting international quality standards and establishing reliable distribution networks. Merck KGaA (MilliporeSigma) leverages its broad pharmaceutical ingredient portfolio and established global logistics to serve a diverse range of clients, from large pharmaceutical companies to research institutions.

What Are the Quality Specifications for Pharmaceutical-Grade Hydroxocobalamin?

Pharmaceutical-grade hydroxocobalamin API must meet stringent purity, potency, and safety standards as defined by international pharmacopoeias. These specifications ensure the API is suitable for human use in therapeutic applications.

Key Quality Parameters

Parameter	Specification (Typical, based on USP/Ph. Eur.)	Analytical Method (Examples)	Significance
Assay (Potency)	Not less than 97.0% and not more than 102.0%	HPLC (High-Performance Liquid Chromatography)	Ensures accurate therapeutic dosage.
Identification	Conforms to spectroscopic or chromatographic tests	UV-Vis Spectroscopy, HPLC	Confirms the substance is indeed hydroxocobalamin.
Loss on Drying	Not more than 1.0%	Gravimetric analysis	Controls water content to ensure stability and accurate weighing.
Residue on Ignition	Not more than 0.1%	Sulfated Ash Test	Indicates the level of inorganic impurities.
Heavy Metals	Not more than 10 ppm (parts per million)	Colorimetric or ICP-MS	Essential for safety, as heavy metals are toxic.
Related Substances	Defined limits for specific impurities and total impurities	HPLC, GC (Gas Chromatography)	Controls by-products of synthesis or degradation that could be harmful.
pH	Typically 4.0 to 6.5 for a 0.1% solution	Potentiometric measurement	Affects solubility and stability in solution.
Appearance	Dark red crystalline powder	Visual inspection	A basic quality check for consistency.
Microbial Limits	Complies with pharmacopoeial limits for bacteria, yeast, mold	Microbial enumeration tests	Ensures absence of harmful microorganisms.

Manufacturers must provide a Certificate of Analysis (CoA) with each batch, detailing the results of testing against these specifications. Ongoing stability studies are also crucial to determine the shelf-life of the API under specified storage conditions (e.g., protected from light).

What is the Role of Hydroxocobalamin in Pharmaceutical Applications?

Hydroxocobalamin is primarily utilized as an active pharmaceutical ingredient (API) in two main therapeutic categories: the treatment of cyanide poisoning and the management of vitamin B12 deficiency.

Cyanide Poisoning Antidote

Mechanism of Action: Hydroxocobalamin binds to cyanide ions (CN-) with high affinity, forming a stable, non-toxic cyanocobalamin (vitamin B12) molecule that can be excreted by the kidneys. This mechanism rapidly sequets cyanide, preventing it from inhibiting cytochrome c oxidase, a critical enzyme in cellular respiration.
Therapeutic Use: It is administered intravenously as a rapid-acting antidote for acute cyanide poisoning, which can result from industrial chemical exposure (e.g., fires involving synthetic materials), certain medical treatments, or intentional ingestion.
Product Examples: Fresenius Kabi's Cyanokit® is a well-known branded product containing hydroxocobalamin for this indication.

Vitamin B12 Deficiency Treatment

Role of Vitamin B12: Vitamin B12 is essential for DNA synthesis, red blood cell formation, and neurological function. Deficiency can lead to megaloblastic anemia, pernicious anemia, and severe neurological damage.
Therapeutic Use: Hydroxocobalamin is used to treat vitamin B12 deficiency, particularly in individuals who cannot absorb vitamin B12 from the gastrointestinal tract (e.g., due to malabsorption disorders or surgical removal of parts of the stomach or intestine). It is also used for certain metabolic disorders.
Administration: It is administered via intramuscular or intravenous injection. Hydroxocobalamin is a naturally occurring form of vitamin B12 and is converted to its active coenzyme forms, methylcobalamin and adenosylcobalamin, within the body.

Key Takeaways

The global hydroxocobalamin API market is served by specialized pharmaceutical chemical manufacturers, with Fresenius Kabi AG being a prominent integrated supplier for cyanide antidote kits.
Key API suppliers include Merck KGaA (MilliporeSigma), Shin Poong Pharmaceutical, Nanjing Legend Biotechnology, and Qilu Pharmaceutical, catering to both emergency medicine and vitamin deficiency treatment markets.
Production requires strict adherence to cGMP and regulatory approvals from bodies like the FDA and EMA, including DMF or APIMF filings and compliance with pharmacopoeia monographs (USP, Ph. Eur.).
Market dynamics are driven by the critical role of hydroxocobalamin in treating cyanide poisoning and vitamin B12 deficiency, alongside opportunities in the generic drug sector.
Pharmaceutical-grade hydroxocobalamin API must meet stringent quality specifications for assay, purity, heavy metals, and microbial contamination to ensure patient safety and therapeutic efficacy.

FAQs

What is the primary difference between hydroxocobalamin and cyanocobalamin in terms of pharmaceutical use? Hydroxocobalamin is primarily used as an immediate-acting antidote for cyanide poisoning by binding free cyanide ions. It is also a therapeutic form of vitamin B12. Cyanocobalamin is the most common synthetic form of vitamin B12 used for treating deficiencies, but it does not possess the rapid cyanide-binding properties of hydroxocobalamin.
Are there specific storage conditions required for hydroxocobalamin API? Yes, hydroxocobalamin API is typically sensitive to light and should be stored in well-closed, light-resistant containers at controlled room temperature or as specified by the manufacturer's stability data to maintain its potency and prevent degradation.
What is the typical lead time for sourcing hydroxocobalamin API from major suppliers? Lead times can vary significantly based on the supplier's production schedules, current inventory, order volume, and the client's regulatory status. For large quantities or new clients, lead times can range from 8 to 24 weeks, especially if batch production needs to be scheduled.
Does the manufacturing process for hydroxocobalamin involve any specific hazardous materials? The synthesis of complex organic molecules like hydroxocobalamin may involve the use of various reagents and solvents. Manufacturers are required to have robust safety protocols in place to manage any hazardous materials used during the chemical synthesis process and to ensure no harmful residues remain in the final API.
What are the implications of impurities in hydroxocobalamin API for patient safety? Impurities, if not controlled within pharmacopoeial limits, can pose significant risks to patient safety. They can reduce the API's efficacy, cause adverse drug reactions, or exhibit their own toxic effects. Rigorous quality control and analytical testing are therefore essential to identify and quantify any impurities.

Citations

[1] Fresenius Kabi AG. (n.d.). Cyanokit. Retrieved from [Fresenius Kabi website (example - actual URL would be specific product page)] [2] Merck KGaA. (n.d.). Pharmaceutical Ingredients. Retrieved from [Merck KGaA website (example - actual URL would be specific product page)] [3] Shin Poong Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Shin Poong Pharmaceutical website (example - actual URL would be specific product page)] [4] Nanjing Legend Biotechnology Co., Ltd. (n.d.). API Catalog. Retrieved from [Nanjing Legend Biotechnology website (example - actual URL would be specific product page)] [5] Qilu Pharmaceutical Co., Ltd. (n.d.). APIs. Retrieved from [Qilu Pharmaceutical website (example - actual URL would be specific product page)] [6] U.S. Food and Drug Administration. (2023). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA website] [7] European Medicines Agency. (2022). EudraLex Volume 4 - Good Manufacturing Practice. Retrieved from [EMA website] [8] United States Pharmacopeia. (n.d.). Hydroxocobalamin Monograph. Retrieved from [USP website (subscription required)] [9] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM website]

Suppliers and packagers for generic pharmaceutical drug: hydroxocobalamin